Basic Stats
| LEI | NSLL8ITTRR0J5HEMR848 |
| CIK | 1048477 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioMarin Pharmaceutical Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BioMarin Pharmaceutical Inc. |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025 S-8 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No. |
|
| August 5, 2025 |
BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended on April 1, 2025. Exhibit 10.2 BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, As Amended April 1, 2025 Adopted by the Compensation Committee of the Board of Directors: April 10, 2017 Approved by the Stockholders: June 6, 2017 Amended by the Compensation Committee of the Board of Directors: April 12, 2019 Amendment Approved by the Stockholders: June 4, 2019 Amended by the Compensation Committee of the Boar |
|
| August 4, 2025 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organi |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identi |
|
| July 1, 2025 |
Press Release issued by BioMarin Pharmaceutical Inc., dated July 1, 2025. Exhibit (a)(5)(ix) Contacts: Investors Media Traci McCarty Erin Rau BioMarin Pharmaceutical Inc. |
|
| June 17, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Perso |
|
| June 13, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Perso |
|
| June 13, 2025 |
CORRESP BioMarin June 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Daniel Duchovny, Division of Corporation Finance, Office of Mergers & Acquisitions Re: BioMarin Pharmaceutical Inc. Inozyme Pharma, Inc. Schedule TO-T Filed June 2, 2025 File No. 005-91586 Dear Mr. Duchovny, This letter responds to the comm |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identi |
|
| June 2, 2025 |
Exhibit (d)(4) BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949 May 10, 2025 Inozyme Pharma, Inc. 321 Summer Street, Suite 400 Boston, MA 02210 Attention: Board of Directors Re: Project Ingrid - Exclusivity Ladies and Gentlemen: BioMarin Pharmaceutical Inc. (“Purchaser”) and Inozyme Pharma, Inc. (the “Company”) wish to continue to engage in negotiations regarding a possible |
|
| June 2, 2025 |
Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC. |
|
| June 2, 2025 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(iii) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC. |
|
| June 2, 2025 |
Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of INOZYME PHARMA, INC. |
|
| June 2, 2025 |
Exhibit (d)(3) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (the “Agreement”), is effective as of May 8, 2024 (the “Effective Date”), and is made by and between BioMarin Pharmaceutical Inc. |
|
| June 2, 2025 |
Form of Notice of Guaranteed Delivery. Exhibit (a)(1)(v) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of INOZYME PHARMA, INC. |
|
| June 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) INOZYME PHARMA, INC. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly-Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Parent of Offeror) (Names of Filing Persons (identifying status as of |
|
| June 2, 2025 |
Summary Advertisement, as published in The Wall Street Journal on June 2, 2025. Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| June 2, 2025 |
Offer to Purchase, dated as of June 2, 2025. Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of INOZYME PHARMA, INC. |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiz |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu |
|
| May 19, 2025 |
Presentation to Inozyme Employees dated May 19, 2025 Exhibit 99.2 Introductory Meeting Alexander Hardy President & CEO May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMa |
|
| May 19, 2025 |
Transcript from BioMarin Business Update Call dated May 16, 2025 Exhibit 99.1 16-May-2025 BioMarin Pharmaceutical Inc. (BMRN) Business Update Call CORPORATE PARTICIPANTS Traci McCarty Group Vice President-Investor Relations, BioMarin Pharmaceutical Inc. Alexander Hardy President, Chief Executive Officer & Director, BioMarin Pharmaceutical Inc. Gregory Friberg Executive Vice President, Chief Research & Development Officer, BioMarin Pharmaceutical Inc. Brian R. M |
|
| May 19, 2025 |
Presentation to BioMarin Employees dated May 19, 2025 Exhibit 99.1 Inozyme Acquisition May 19, 2025 1 Forward-Looking Statements Forward-Looking Statements This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMarin, including, without limitatio |
|
| May 16, 2025 |
Exhibit 99.1 BioMarin Contacts Inozyme Contacts Traci McCarty, Investors Stefan Riley, Investors BioMarin Pharmaceutical Inc. Inozyme Pharma, Inc. (415) 455-7558 (617) 461-2442 Marni Kottle, Media Todd Cooper, Media BioMarin Pharmaceutical Inc. Biongage Communications (415) 218-7111 (617) 840-1637 FOR IMMEDIATE RELEASE BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 INOZYME PHARMA, INC. (Name of Subject Company (Issuer)) INCLINE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of BIOMARIN PHARMACEUTICAL INC. (Offeror) (Name of Filing Persons (identifying status as offeror, issu |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiz |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiz |
|
| May 16, 2025 |
BioMarin Social Media Content dated May 16, 2025 Exhibit 99.3 BioMarin Pharmaceutical Inc. LinkedIn Post We’re excited to share that today we announced a definitive agreement to acquire Inozyme Pharma, a clinical-stage biopharmaceutical company advancing an innovative enzyme replacement therapy for ENPP1 Deficiency, a condition with no currently approved treatments. ENPP1 Deficiency is a rare, serious and progressive genetic condition that affec |
|
| May 16, 2025 |
Letter to Inozyme Employees dated May 16, 2025 Exhibit 99.2 BMRN-INZY Letter to INZY Employees To: Inozyme Employees Date: May 16, 2025 Dear Inozyme, I am reaching out today on behalf of BioMarin to share my excitement about the opportunity to bring INZ-701 to patients with ENPP1 Deficiency. Your team has done important work to evaluate the safety and efficacy profile of INZ-701, successfully advancing it into Phase 3 development. As I have go |
|
| May 16, 2025 |
Letter to BioMarin Employees dated May 16, 2025 Exhibit 99.1 BMRN-INZY Letter to BMRN Employees Subject: BioMarin to Acquire Inozyme Pharma To: BioMarin Employees Date: May 16, 2025 Dear BioMarin, Today marks an important milestone for BioMarin, with the announcement of our agreement to acquire Inozyme Pharma, which will add a Phase 3 enzyme replacement therapy to our portfolio. The therapy, INZ-701, treats ENPP1 deficiency, a rare and lifelong |
|
| May 16, 2025 |
Form of Tender and Support Agreement. EX-10.1 Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”), dated as of May 16, 2025, is entered into by and between BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”), and the undersigned stockholder of Inozyme Pharma, Inc., a Delaware corporation (the “Company”), listed on Exhibit A hereto (the, “Stockholder”). Capitalized terms used but n |
|
| May 16, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: INOZYME PHARMA, INC., BIOMARIN PHARMACEUTICAL INC., and INCLINE MERGER SUB, INC. Dated as of May 16, 2025 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE 2 THE OFFER 16 Section 2.1 The Offer 16 Section 2.2 Company Actions 19 ARTICLE 3 MERGER TRANSACTION 21 Section 3.1 Merger of Merger Sub into the Company 21 Se |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiza |
|
| May 1, 2025 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 3, 2025 |
Amended and Restated Bylaws of BioMarin Pharmaceutical Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOMARIN PHARMACEUTICAL INC. Amended and Restated: February 25, 2025 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders’ Meetings 1 2.5 Manner of Giving Notice; Affidavit of Notic |
|
| March 3, 2025 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 BIOMARIN PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation) (Com |
|
| February 24, 2025 |
BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Exhibit 10.22 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation The summary below sets forth the compensation received by independent directors serving on the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”). This summary is consistent with what was reported in the Company’s proxy statement previously filed with the Securities and Exchange Co |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2025 BIOMARIN PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation) (Com |
|
| February 24, 2025 |
Exhibit 19.1 Corporate Business Policy Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities PURPOSE This Insider Trading Policy (the “Policy”) provides guidelines to officers and other employees of BioMarin Pharmaceutical Inc. (the “Company”) and members of the Company’s Board of Directors (the “Directors”) with respect to transactions in the Company’s s |
|
| February 24, 2025 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2024 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 19, 2025 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability |
|
| February 19, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| October 31, 2024 |
BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation. Exhibit 10.2 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation The summary below sets forth the compensation received by independent directors serving on the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”). This summary is consistent with what was reported in the Company’s proxy statement previously filed with the Securities and Exchange Com |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| October 29, 2024 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y) |
|
| September 30, 2024 |
BMRN / BioMarin Pharmaceutical Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. ) BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09061G101 |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or o |
|
| September 16, 2024 |
105 Digital Drive . Novato, CA 94949 . Tel 415.506.6700 . Fax 415.382.7889 . www.BMRN.com BioMarin September 16, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N. |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or orga |
|
| September 4, 2024 |
Credit Agreement, dated as of August 28, 2024, by and among BioMarin Pharmaceutical Inc., as the Exhibit 10.1 EXECUTION COPY CREDIT AGREEMENT Dated as of August 28, 2024 among BIOMARIN PHARMACEUTICAL INC., as the Borrower, CITIBANK, N.A., as Administrative Agent, BANK OF AMERICA, N.A., JPMORGAN CHASE BANK, N.A., U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndication Agents and the other Lenders from time to time party hereto CITIBANK, N.A., BofA SECURITIES, |
|
| August 28, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or orga |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2024 BIOMARIN PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation) (Commi |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| August 5, 2024 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.3 |
|
| August 5, 2024 |
Exhibit 10.1 AMENDMENT TO CONSULTING AGREEMENT This Amendment (this “Amendment”), entered into and effective as of June 8, 2024 (the “Effective Date”), is made by and between BioMarin Pharmaceutical Inc. (“BioMarin”), a Delaware corporation, located at 105 Digital Drive, Novato, CA 94949 and Jean-Jacques Bienaime (“Provider”). WHEREAS, BioMarin and Provider entered into a Consulting Agreement on O |
|
| August 5, 2024 |
ioMarin Pharmaceutical Inc. Summary of Indep Exhibit 10.2 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation The summary below sets forth the compensation received by independent directors serving on the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”). This summary is consistent with what was reported in the Company’s proxy statement previously filed with the Securities and Exchange Com |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| July 10, 2024 |
BMRN / BioMarin Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0026-biomarinpharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: BioMarin Pharmaceutical Inc Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: June 28, 2024 Check the appropriate box t |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 14, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiza |
|
| April 26, 2024 |
Exhibit 10.1 Elliott Associates, L.P. Elliott International, L.P. c/o Elliott Investment Management L.P. 360 S. Rosemary Ave., 18th floor West Palm Beach, FL 33401 DELIVERED BY E-MAIL April 11, 2024 BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949 Attention: Eric Davis, Chief Legal Officer Email: [email protected] Dear Sirs / Madams: Reference is made to that certain Cooperati |
|
| April 26, 2024 |
Exhibit 18.1 KPMG LLP Suite 1400 55 Second Street San Francisco, CA 94105 April 26, 2024 The Board of Directors BioMarin Pharmaceutical Inc. San Rafael, California Ladies and Gentlemen: We have been furnished with a copy of the quarterly report on Form 10-Q of BioMarin Pharmaceutical Inc and subsidiaries (the Company) for the three months ended March 31, 2024, and have read the Company’s statement |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 24, 2024 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Ea |
|
| April 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2024 BIOMARIN PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation) (Commiss |
|
| April 23, 2024 |
Exhibit 99.1 EFiled: Mar 27 2024 12:01PM EDT Transaction ID 72616079 Case No. Multi-Case IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ELAINE WANG, derivatively on : behalf of BIOMARIN : PHARMACEUTICAL INC., : : C.A. No. 2023-0058-NAC Plaintiff, : : v. : : JEAN-JACQUES BIENAIMÉ, : ELIZABETH MCKEE ANDERSON, : WILLARD DERE, ELAINE J. : HERON, ROBERT HOMBACH, : BRYAN LAWLIS, RICHARD A. : MEIER, D |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 26, 2024 |
Dodd-Frank Incentive Compensation Recoupment Policy Exhibit 97.1 BIOMARIN PHARMACEUTICAL INC. Dodd-Frank Incentive Compensation Recoupment Policy (adopted October 4, 2023) 1.Introduction The Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Dodd-Frank Incentive Compensation Recoupment Policy (this |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 26, 2024 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2023 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| February 22, 2024 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 Total FY’23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $ |
|
| February 13, 2024 |
BMRN / BioMarin Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0437-biomarinpharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: BioMarin Pharmaceutical Inc Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b |
|
| February 13, 2024 |
BMRN / BioMarin Pharmaceutical Inc. / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d776250dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3 )* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 12, 2024 |
SC 13G/A 1 bmrna2421224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 24)* BioMarin Pharmaceutical Inc. (Name of Issuer) COM (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 20, 2023 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of December 20, 2023 (the “Effective Date”), is by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party,” and together, the “Elliott |
|
| December 20, 2023 |
Exhibit 99.1 Contacts: Investors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 218-7111 BioMarin Announces Governance Enhancements and Value Creation Initiatives Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 3, 2023 |
Exhibit 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of October 30, 2023 by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Alexander Hardy (“Employee”). NOW THEREFORE, for good and valuable consideration (the receipt and adequacy of which are hereby acknowledged and agreed) the parties hereby covenant and agree as follow |
|
| November 3, 2023 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) dated October 30, 2023 is between Jean-Jacques Bienaime and BioMarin Pharmaceutical Inc., including any past or present parents, subsidiaries, affiliates, entities and divisions (collectively, the “Company”). The parties agree to the following: 1. Separation. Your last day of work with |
|
| November 3, 2023 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into on October 30, 2023 to be effective December 1, 2023 (the “Effective Date”), and is made by and between BioMarin Pharmaceutical Inc., (“BioMarin”), a Delaware corporation, located at 105 Digital Drive, Novato, CA 94949, and Jean-Jacques Bienaime (“Provider”). BioMarin and Provider are each individually re |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 2, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BioMarin Pharmaceutical Inc. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 As filed with the Securities and Exchange Commission on November 2, 2023 Registration No. |
|
| November 1, 2023 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year •Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net P |
|
| November 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| August 2, 2023 |
BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as Exhibit 10.1 BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, As Amended April 3, 2023 Adopted by the Compensation Committee of the Board of Directors: April 10, 2017 Approved by the Stockholders: June 6, 2017 Amended by the Compensation Committee of the Board of Directors: April 12, 2019 Amendment Approved by the Stockholders: June 4, 2019 Amended by the Compensation Committee of the Boar |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organi |
|
| July 31, 2023 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date •VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 26, 2023 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues •Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance •Full-year |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| April 11, 2023 |
2023 Proxy Statement Annual Meeting: May 23, 2023 10:00 a.m. Pacific TimePioneers in Rare Disease Founded in 1997, BioMarin Pharmaceutical Inc. (we, us, our, BioMarin or the Company) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin’s rob |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 6, 2023 |
105 Digital Drive . Novato, CA 94949 . Tel 415.506.6700 . Fax 415.382.7889 . www.BMRN.com April 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N. |
|
| February 27, 2023 |
Exhibit 10.35 BIOMARIN PHARMACEUTICAL INC. 2017 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT BioMarin Pharmaceutical Inc. (the “Company”) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the “Plan”) hereby grants you a number of restricted stock units (“RSUs”) in the amount set forth below (the “Award”). The Award is subject to all of the terms and |
|
| February 27, 2023 |
Form of Stock Options Agreement for the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan Exhibit 10.37 BIOMARIN PHARMACEUTICAL INC. 2017 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT BioMarin Pharmaceutical Inc. (the “Company”) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the “Plan”) hereby grants you an option to purchase the number of shares of Common Stock in the amount set forth below (the “Option”). The Option is subject to all of the t |
|
| February 27, 2023 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2022 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 27, 2023 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business •VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Bi |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| February 27, 2023 |
Exhibit 10.36 BIOMARIN PHARMACEUTICAL INC. 2017 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT BioMarin Pharmaceutical Inc. (the “Company”) pursuant to its 2017 Equity Incentive Plan, as it may be amended from time to time (the “Plan”) hereby grants you a number of restricted stock units (“RSUs”) in the amount set forth below (the “Award”). The Award is subject to all of the terms and |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 14, 2023 |
BMRN / BioMarin Pharmaceutical Inc. / DODGE & COX - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 13, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12 )* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2023 |
BMRN / BioMarin Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: BioMarin Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2023 |
SC 13G/A 1 bmrna2320923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 23)* BioMarin Pharmaceutical Inc. (Name of Issuer) COM (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| February 3, 2023 |
BMRN / BioMarin Pharmaceutical Inc. / BlackRock Inc. Passive Investment us09061g1013020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) BIOMARIN PHARMACEUTICAL INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 09061G101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 11, 2023 |
EX-99.1 Exhibit 99.1 • 41st Annual J.P. Morgan ai0MARIN Healthcare Conference January 9, 2023 Transforming Lives Through Genetic Discovery J.J. Bienaime Chairman and Chief Executive Officer Safe Harbor This non -confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 21, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOMARIN PHARMACEUTICAL INC. Amended and Restated: December 15, 2022 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 1 2.5 Manner of Giving Notice; Affidavit of Notic |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 28, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED BIOMARIN PHARMACEUTICAL INC. NONQUALIFIED DEFERRED COMPENSATION PLAN (THE ?PLAN?) (as amended and restated on October 7, 2014) Effective Date: October 4, 2022 1.Subsection 3.1(c) of the Plan is amended and restated in its entirety to read as follows: Irrevocable Election. The Participant?s Election with respect to his or her Compensation Def |
|
| October 28, 2022 |
BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Exhibit 10.2 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Effective as of October 5, 2022, the Board of Directors (the ?Board?) of BioMarin Pharmaceutical Inc. (the ?Company?) approved revised compensation for the independent directors of the Company, with the only change being an increase in the Corporate Governance and Nominating Committee Member annual cash compensa |
|
| October 26, 2022 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) •VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Be |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| October 7, 2022 |
Costs Associated with Exit or Disposal Activities SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| August 3, 2022 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance ?VOXZOGO? $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter; Total Revenues Grew 13% Year-Over-Yea |
|
| May 31, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organiza |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 29, 2022 |
Exhibit 10.1 Execution Version CERTAIN INFORMATION, IDENTIFIED BY, AND REPLACED WITH, A MARK OF ?[***]? HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Asset Purchase Agreement by and between Eli Lilly and Company, BioMarin Pharmaceutical Inc., And BioMarin International Ltd. February 8, 2022 Asset Purchase |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| April 27, 2022 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Record Revenues in First Quarter 2022 •BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-over-Year, Excluding Kuvan •Full-year |
|
| April 12, 2022 | ||
| April 12, 2022 |
DEF 14A 1 bmrn3994571-def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confident |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 25, 2022 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2021 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 25, 2022 |
Exhibit 10.32 SECOND AMENDMENT TO THE AMENDED AND RESTATED BIOMARIN PHARMACEUTICAL INC. NONQUALIFIED DEFERRED COMPENSATION PLAN (the ?Plan?) (as amended and restated on October 7, 2014) Effective Date: October 5, 2021 1.Subsection 1.25 of the Plan is amended and restated in its entirety to read as follows: [intentionally omitted] 2.Section 5.1 of the Plan is amended and restated in its entirety to |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| February 23, 2022 |
CORRESP 1 filename1.htm February 23, 2022 VIA EDGAR *FOIA Confidential Treatment Request* Confidential Treatment Requested by BioMarin Pharmaceutical Inc. in connection with comments relating to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (File No. 000-26727) United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sci |
|
| February 23, 2022 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates ?Full-year 2021 Total Revenues of $1.85 Billion; Revenues Excluding Kuvan Increased 11% Year-Over-Year ?Company Provides Full-Year 2022 Total Reve |
|
| February 17, 2022 |
BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended April 5, 2021. Exhibit 99.1 BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, As Amended April 5, 2021 Adopted by the Compensation Committee of the Board of Directors: April 10, 2017 Approved by the Stockholders: June 6, 2017 Amended by the Compensation Committee of the Board of Directors: April 12, 2019 Amendment Approved by the Stockholders: June 4, 2019 Amended by the Compensation Committee of the Boar |
|
| February 17, 2022 |
As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 17, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BioMarin Pharmaceutical Inc. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| February 14, 2022 |
BioMarin Sells Priority Review Voucher for $110 Million Exhibit 99.1 BioMarin Sells Priority Review Voucher for $110 Million SAN RAFAEL, Calif., Feb. 9, 2022?SAN RAFAEL, Calif.,?BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in November 2021 for a lump sum payment of $110,000,000. The Com |
|
| February 14, 2022 |
BMRN / BioMarin Pharmaceutical Inc. / DODGE & COX - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 22)* BioMarin Pharmaceutical Inc. (Name of Issuer) COM (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 9, 2022 |
BMRN / BioMarin Pharmaceutical Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: BioMarin Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11 )* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| December 20, 2021 |
105 Digital Drive . Novato, CA 94949 . Tel 415.506.6700 . Fax 415.382.7889 . www.BMRN.com December 20, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N. |
|
| December 15, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 3, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 27, 2021 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates ?Strong Commercial Launch of VOXZOGO? for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding, Target A |
|
| October 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| July 30, 2021 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT FIRST AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?), dated as of May 28, 2021, by and among BIOMARIN PHARMACEUTICAL INC., a Delaware corporation (the ?Borrower?), CALIFORNIA CORPORATE CENTER ACQUISITION LLC, a Delaware limited liability company (the ?Guarantor?), the Lenders party hereto, BANK OF AMERICA, N.A., as Administrative |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organi |
|
| July 28, 2021 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates ?Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020 ?Raising Full-year 2021 Financial Guidance ?Marketing Authorization Applicat |
|
| June 2, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 29, 2021 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates •Full-year 2021 Financial Guidance Reaffirmed •Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan •Regulatory Actio |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| April 13, 2021 | ||
| April 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| April 13, 2021 |
- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 8, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 26, 2021 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2020 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Holdings Inc BioMarin Pharmaceutical Inc. 100% Delaware BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 26, 2021 |
Part-Time Employment Agreement with Robert A. Baffi, Ph.D. effective January 1, 2021. Exhibit 10.32 PART-TIME EMPLOYMENT AGREEMENT THIS PART-TIME EMPLOYMENT AGREEMENT (?Agreement?) is made effective as of January 1, 2021 (?Effective Date?) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the ?Company?) and Robert A Baffi, Ph.D. (?Employee?). WHEREAS, Employee currently serves as Senior Advisor to the Company, a full-time position, pursuant to the Amended and Res |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or or |
|
| February 25, 2021 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates ?Full-year 2020 Total Revenues Increased 9% to $1.86 billion ?Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Ther |
|
| February 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 11, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: BioMarin Pharmaceutical Inc. Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 7, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| December 18, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOMARIN PHARMACEUTICAL INC. Amended and Restated: December 15, 2020 Table of Contents Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders’ Meetings 1 2.5 Manner of Giving Notice; Affidavit o |
|
| December 18, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| November 5, 2020 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million •Top-line Results from 52-week Phase 3 Study with Valoctocogene Roxaparvovec for Severe Hemophilia A Expected Early 2021 •Submission of Phase 3 Results from 134 Subjects |
|
| September 10, 2020 |
BMRN / BioMarin Pharmaceutical, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| September 9, 2020 |
Regulation FD Disclosure - 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 4, 2020 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million •U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A under Priority Review by Food and Drug Administration (FDA) with Prescrip |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| July 2, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 1, 2020 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 19, 2020 |
EX-99.1 Exhibit 99.1 Contacts: Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027 SAN RAFAEL, Calif., May 19, 2020 — BioMarin |
|
| May 19, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 14, 2020 |
EX-4.1 Exhibit 4.1 Execution Version INDENTURE DATED AS OF MAY 14, 2020 BETWEEN BIOMARIN PHARMACEUTICAL INC. AND U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE 1.25% Convertible Senior Subordinated Notes due 2027 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01 Definitions 1 Section 1.02 Other Definitions 14 Section 1.03 Rules of Construction 15 Section 1.04 Act |
|
| May 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 14, 2020 |
EX-99.1 Exhibit 99.1 Contacts: Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes SAN RAFAEL, Calif., May 11, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it inte |
|
| May 14, 2020 |
BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering EX-99.2 Exhibit 99.2 Contacts: Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 For Immediate Release: BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering SAN RAFAEL, Calif., May 11, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the pricing of $ |
|
| May 1, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2020 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or organ |
|
| April 29, 2020 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million •U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA under Priority Review with Prescription Drug User Fee Act |
|
| April 22, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 BioMarin Pharmaceutical Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 14, 2020 |
BMRN / BioMarin Pharmaceutical, Inc. DEFA14A - - DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2020 |
PROXY STATEMENT Annual Meeting: May 27 , 2020, 9:00 a.m. Pacific Time Notice of Annual Meeting of Stockholders Dear Stockholder of BioMarin: You are cordially invited to attend the Annual Meeting of Stockholders (the Annual Meeting) of BioMarin Pharmaceutical Inc., a Delaware corporation (we, us, BioMarin or the Company). The Annual Meeting will be held on Wednesday, May 27, 2020 at 9:00 a.m. (Pac |
|
| April 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pha |
|
| February 27, 2020 |
Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 500,000,000 shares of common stock, $0.001 par value per share, and 1,000,000 shares of preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. F |
|
| February 27, 2020 |
Subsidiaries of BioMarin Pharmaceutical Inc. Exhibit 21.1 Subsidiaries of BioMarin Pharmaceutical Inc. as of December 31, 2019 Name Direct Parent Ownership Jurisdiction of Incorporation BioMarin Commercial Ltd BioMarin Pharmaceutical Inc. 100% Ireland BioMarin International Holdings Inc BioMarin Pharmaceutical Inc. 100% Delaware BioMarin International Ltd BioMarin Commercial Ltd. 100% Ireland |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 BioMarin Pharmaceutical Inc (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of incorporation or org |
|
| February 26, 2020 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results •Full-year 2019 Total Revenues Increased 14% to $1.7 billion •17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in Full-yea |
|
| February 12, 2020 |
BMRN / BioMarin Pharmaceutical, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 12, 2020 |
BMRN / BioMarin Pharmaceutical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: BioMarin Pharmaceutical Inc Title of Class of Securities: Common Stock CUSIP Number: 09061G101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 6, 2020 |
BMRN / BioMarin Pharmaceutical, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 3, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 4, 2019 |
EX-10.1 2 exhibit101-30sep19x10q.htm EXHIBIT 10.1 Exhibit 10.1 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Effective as of September 19, 2019, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved revised compensation for the independent directors of the Company. All independent directors are entitled to receive a combination of |
|
| November 4, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 29, 2019 |
BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Exhibit 10.1 BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation Effective as of September 19, 2019, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved revised compensation for the independent directors of the Company. All independent directors are entitled to receive a combination of annual cash retainers and restricted stock unit ( |
|
| October 29, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 23, 2019 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Third Quarter 2019 Financial Results - The Company Achieved Record Total Revenues of $461.1 million; Increased 18% Year Over Year - Full-year GAAP Loss and Non-GAAP Income Guidance Improved to Top-end of Range Driven by |
|
| October 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 16, 2019 |
BMRN / BioMarin Pharmaceutical, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on October 16, 2019 Registration No. |
|
| August 2, 2019 |
Exhibit 10.2 BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan, As Amended and Restated April 12, 2019 The following constitutes the provisions of the BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan of BioMarin Pharmaceutical Inc. (the “Company”), which is an amendment and restatement of the Company’s 1998 Employee Stock Purchas |
|
| August 2, 2019 |
Exhibit 10.1 FIRST AMENDMENT TO THE AMENDED AND RESTATED BIOMARIN PHARMACEUTICAL INC. (the “Company”) NONQUALIFIED DEFERRED COMPENSATION PLAN (the “Plan”) (as amended and restated on October 7, 2014) Effective Date: June 4, 2019 1. Subsection 1.26 of the Plan is amended and restated in its entirety to read as follows: 1.26 “Restricted Stock Compensation,” means any restricted stock, restricted sto |
|
| August 2, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 2, 2019 |
Exhibit 10.3 BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, As Amended April 12, 2019 Adopted by the Compensation Committee of the Board of Directors: April 10, 2017 Approved by the Stockholders: June 6, 2017 Amended by the Compensation Committee of the Board of Directors: April 12, 2019 Amendment Approved by the Stockholders: June 4, 2019 1. General. (a) Successor to and Continuation of |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 1, 2019 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces Second Quarter 2019 Financial Results - Total Revenues of $387.8 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of June 30, 2019, 551 U.S |
|
| July 10, 2019 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2019 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 7, 2019 |
8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2019 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-26727 BioMari |
|
| April 25, 2019 |
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Debra Charlesworth BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (415) 455-7451 BioMarin Announces First Quarter 2019 Financial Results - Total Revenues Top $400 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of March 31, 2019, 414 U.S. |
|
| April 25, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2019 BioMarin Pharmaceutical Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-26727 68-0397820 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 23, 2019 |
BMRN / BioMarin Pharmaceutical, Inc. DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 23, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by |
|
| April 23, 2019 |
PROXY STATEMENT Annual Meeting: June 4, 2019, 9:00 a.m. Pacific Time BioMarin Morning Glory Conference Room 750 Lindaro Street San Rafael, CA 94901 Notice of Annual Meeting of Stockholders Dear Stockholder of BioMarin: You are cordially invited to attend the Annual Meeting of the Stockholders (the Annual Meeting) of BioMarin Pharmaceutical Inc., a Delaware corporation (we, us, BioMarin or the Comp |
